Elise Alspach

3.2k total citations · 1 hit paper
19 papers, 1.7k citations indexed

About

Elise Alspach is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Elise Alspach has authored 19 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Elise Alspach's work include Telomeres, Telomerase, and Senescence (7 papers), Immunotherapy and Immune Responses (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Elise Alspach is often cited by papers focused on Telomeres, Telomerase, and Senescence (7 papers), Immunotherapy and Immune Responses (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Elise Alspach collaborates with scholars based in United States, Russia and Ireland. Elise Alspach's co-authors include Robert D. Schreiber, Danielle M. Lussier, Sheila A. Stewart, Megan K. Ruhland, Ermira Pazolli, Kevin C. Flanagan, David Piwnica‐Worms, Xianmin Luo, Julie L. Prior and K. Leahy and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Elise Alspach

19 papers receiving 1.6k citations

Hit Papers

Interferon γ and Its Impo... 2018 2026 2020 2023 2018 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elise Alspach United States 14 856 679 632 405 210 19 1.7k
Deblina Raychaudhuri India 11 604 0.7× 461 0.7× 408 0.6× 128 0.3× 173 0.8× 17 1.2k
Panagiotis Karagiannis United Kingdom 19 558 0.7× 420 0.6× 486 0.8× 158 0.4× 102 0.5× 42 1.5k
Tomohisa Baba Japan 26 865 1.0× 756 1.1× 597 0.9× 98 0.2× 180 0.9× 54 1.8k
Katharina Wolter Germany 5 787 0.9× 205 0.3× 678 1.1× 431 1.1× 145 0.7× 14 1.3k
Tomer‐Meir Salame Israel 15 738 0.9× 308 0.5× 697 1.1× 106 0.3× 188 0.9× 23 1.5k
Lydia Dyck Ireland 11 917 1.1× 548 0.8× 527 0.8× 111 0.3× 414 2.0× 12 1.6k
Reem Saleh Qatar 18 889 1.0× 784 1.2× 444 0.7× 70 0.2× 165 0.8× 39 1.7k
Susan M. Kaech United States 9 1.8k 2.1× 779 1.1× 713 1.1× 88 0.2× 520 2.5× 11 2.6k
Thomas Jostock Germany 19 582 0.7× 712 1.0× 752 1.2× 109 0.3× 135 0.6× 32 1.7k
Julien Cherfils‐Vicini France 13 1.3k 1.5× 556 0.8× 413 0.7× 90 0.2× 211 1.0× 22 1.8k

Countries citing papers authored by Elise Alspach

Since Specialization
Citations

This map shows the geographic impact of Elise Alspach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elise Alspach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elise Alspach more than expected).

Fields of papers citing papers by Elise Alspach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elise Alspach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elise Alspach. The network helps show where Elise Alspach may publish in the future.

Co-authorship network of co-authors of Elise Alspach

This figure shows the co-authorship network connecting the top 25 collaborators of Elise Alspach. A scholar is included among the top collaborators of Elise Alspach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elise Alspach. Elise Alspach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Donlin, Maureen J., et al.. (2024). T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer. Cancer Immunology Research. 12(8). 956–963. 4 indexed citations
2.
Keshari, Sunita, Alexander S. Shavkunov, Qi Miao, et al.. (2024). Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Reports. 43(11). 114875–114875. 6 indexed citations
3.
Ebert, E C, Stella G. Hoft, Kelly D. Pyles, et al.. (2024). Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk. Nature Communications. 15(1). 2835–2835. 36 indexed citations
4.
Alspach, Elise, et al.. (2023). Battle Within the Sexes: Differences in Male and Female Immunity and the Impact on Antitumor Responses. Cancer Immunology Research. 12(1). 17–25. 4 indexed citations
5.
Ebert, E C, et al.. (2022). Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer. Frontiers in Immunology. 13. 1022732–1022732. 5 indexed citations
6.
Lussier, Danielle M., Elise Alspach, Jeffrey P. Ward, et al.. (2021). Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences. 118(24). 93 indexed citations
7.
Ruhland, Megan K. & Elise Alspach. (2021). Senescence and Immunoregulation in the Tumor Microenvironment. Frontiers in Cell and Developmental Biology. 9. 754069–754069. 33 indexed citations
8.
Murali, Bhavna, Qihao Ren, Xianmin Luo, et al.. (2018). Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss. Cancer Research. 78(19). 5618–5630. 49 indexed citations
9.
Johnson, Keith A., et al.. (2018). Co-Selection of Mercury- and Antibiotic-Resistance in Hatchery-Reared Salmonids. 2(1). 1 indexed citations
10.
Alspach, Elise, Danielle M. Lussier, & Robert D. Schreiber. (2018). Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harbor Perspectives in Biology. 11(3). a028480–a028480. 386 indexed citations breakdown →
11.
Gubin, Matthew M., Ekaterina Esaulova, Jeffrey P. Ward, et al.. (2018). High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell. 175(4). 1014–1030.e19. 275 indexed citations
12.
Flanagan, Kevin C., Elise Alspach, Ermira Pazolli, et al.. (2017). c-Myb and C/EBPβ regulate OPN and other senescence-associated secretory phenotype factors. Oncotarget. 9(1). 21–36. 20 indexed citations
13.
Marsh, Timothy, Irene Wong, Jaclyn Sceneay, et al.. (2016). Hematopoietic Age at Onset of Triple-Negative Breast Cancer Dictates Disease Aggressiveness and Progression. Cancer Research. 76(10). 2932–2943. 18 indexed citations
14.
Ruhland, Megan K., Andrew J. Loza, Aude-Hélène Capietto, et al.. (2016). Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nature Communications. 7(1). 11762–11762. 350 indexed citations
15.
Parajuli, Shankar P., et al.. (2015). Flap Endonuclease 1 Limits Telomere Fragility on the Leading Strand. Journal of Biological Chemistry. 290(24). 15133–15145. 30 indexed citations
16.
17.
Alspach, Elise, Kevin C. Flanagan, Xianmin Luo, et al.. (2014). p38MAPK Plays a Crucial Role in Stromal-Mediated Tumorigenesis. Cancer Discovery. 4(6). 716–729. 134 indexed citations
18.
Alspach, Elise, Yujie Fu, & Sheila A. Stewart. (2013). Senescence and the Pro-tumorigenic Stroma. Critical Reviews™ in Oncogenesis. 18(6). 549–558. 40 indexed citations
19.
Pazolli, Ermira, et al.. (2012). Chromatin Remodeling Underlies the Senescence-Associated Secretory Phenotype of Tumor Stromal Fibroblasts That Supports Cancer Progression. Cancer Research. 72(9). 2251–2261. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026